t
Diaceutics PLC announced on 24 October 2024 that the High Court of Justice in Northern Ireland confirmed the cancellation of the sum standing to the credit of the Company's share premium account. This Reduction of Capital was approved by shareholders via a special resolution passed at the annual general meeting held on 24 June 2024.
| Date | 24 Oct 2024 |
| Time | 12:53:08 |
| Category | Miscellaneous |
| ID | 5086J |
24 October 2024
Diaceutics plc
(the "Company")
Cancellation of Share Premium Account
Belfast and London, 24 October 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce that earlier today the High Court of Justice in Northern Ireland confirmed the cancellation of the sum standing to the credit of the Company's share premium account (the "Reduction of Capital"). The Reduction of Capital will become effective on registration of the Court order at Companies House, which is expected to occur in the next few days.
The Reduction of Capital, as described in the AGM Notice that was sent to shareholders on 29 May 2024 and which is available on the Company's website (https://investors.diaceutics.com), was approved by way of a special resolution passed by the shareholders of the Company at the annual general meeting held on 24 June 2024.
The purpose of the Reduction of Capital is to create distributable reserves which will provide the Company with flexibility to support, amongst other things, share buy-backs, the funding of the Company's share option schemes and the payment of dividends or other distributions to shareholders in the future.
|
Enquiries: |
|
|
|
|
|
Diaceutics PLC |
Tel: +44 (0)28 9040 6500 |
|
Ryan Keeling, Chief Executive Officer |
|
|
Nick Roberts, Chief Financial Officer
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7523 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees
|
|
|
Alma Strategic Communications |
Tel: +44(0)20 3405 0205 |
|
Caroline Forde, Kinvara Verdon
|
|
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.